Short Bowel Syndrome Market Connected with High Cost of Immunotherapy Treatment as a Part of Heading
The global Short Bowel Syndrome Market is estimated to be valued at US$ 188.9 Bn in 2023 and is expected to exhibit a CAGR of 11.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Short bowel syndrome (SBS) is a malabsorptive disorder that occurs when a significant portion of the small intestine is surgically removed or does not function properly. The small intestine plays a key role in absorbing water and nutrients from food. With SBS, the remaining intestine cannot absorb enough nutrients and water to meet the body's needs. The main clinical manifestations associated with SBS are malnutrition, dehydration, weight loss and diarrhea. SBS treatments help patients obtain adequate hydration and nutrition through parenteral nutrition delivered via a central venous catheter. They improve patients' quality of life by reducing the severity and frequency of diarrhea and related symptoms.
Market key trends:
One of the major trends in the short bowel syndrome market is the high cost of immunotherapy treatment options. Immunotherapy utilizes the body's own immune system to help fight infections and diseases. Several immunotherapies are being investigated for SBS management, such as stem cell therapy and growth factors. However, these treatments involve complex procedures and long-term management, making them very expensive for patients. The high cost poses affordability challenges and limits the uptake of promising immunotherapy options. High prices of such treatments act as a barrier to market growth.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate as the short bowel syndrome market requires high R&D investments. However, new technological advancements may pose threats.
Bargaining power of buyers: The bargaining power of buyers is high due to the availability of substitutes and undifferentiated products.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the presence of many raw material suppliers.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options available for short bowel syndrome currently.
Competitive rivalry: The competition is high among existing players to gain more market share.
Key Takeaways
The Global Short Bowel Syndrome Market Demand is expected to witness high growth, exhibiting CAGR of 11.5% over the forecast period, due to increasing incidence of short bowel syndrome worldwide.
Regional analysis: North America dominates the global short bowel syndrome market due to increasing awareness and availability of advanced treatments. Asia Pacific exhibits the fastest growth over the forecast period attributed to rising healthcare spending in emerging countries such as China and India.
Key players: The key players operating in the short bowel syndrome market are Zealand Pharma, Ardelyx Inc., Emmaus Life Sciences, GLyPharma Therapeutic Inc., OxThera, Shire, Sancilio & Company Inc., Naia Pharmaceuticals. Key players are focusing on developing novel therapies to expand their product portfolio.
Comments
0 comment